skip to Main Content

Our Pipeline

What sets us apart from our peers is our single focus on developing potent and conditionally active T cell targeted immunotherapies for solid tumor cancers with increased tumor specificity and reduced toxicity.

Our COBRA™ pipeline features proprietary and patented conditionally active T cell engaging molecules that we are rapidly accelerating toward the clinic.

Pipeline Graphic v3 060320

Lead Product Candidates

MVC-101 (EGFR x CD3 COBRA™)

Maverick Therapeutics’ lead program candidate, MVC-101, is a proprietary COBRA molecule designed to target Epidermal Growth Factor Receptor (EGFR), a protein expressed on both malignant and healthy tissues. MVC-101 is designed to be a universal solution for patients with EGFR expressing solid tumor cancers. EGFR is expressed on a wide range of solid tumor cancers, including but not limited to colorectal, head & neck, renal, pancreatic, cervical and non small cell lung cancers.

Maverick expects to initiate a Phase 1 trial in Q1 2021.

MVC-280 (B7H3 x CD3 COBRA™)

Maverick Therapeutics’ second program candidate, MVC-280, is a proprietary COBRA molecule designed to target B7H3 (CD276). B7H3 is expressed in a broad range of malignant and healthy tissues, similar to EGFR. MVC-280 is designed to be a universal solution for patients with B7H3 expressing solid tumor cancers. B7H3 is expressed on a wide range of solid tumor cancers, including but not limited to prostate, renal, triple negative breast, head & neck, ovarian and urothelial cancers.

Maverick expects to initiate a Phase 1 trial in H2 2021.

Back To Top